Its activation, triggered by tyrosine kinase receptors, Ras, and integrins, promotes tumor growth and treatment resistance.10 Dysregulation of this pathway is observed in approximately 70% of GBM patients and is correlated with poor prognosis, highlighting its relevance as a therapeutic target. Here, NTRK1 is linked to neoplasm.